Q4 2025 Hansa Biopharma AB Earnings Call Transcript

Feb 11, 2026 / 01:00 PM GMT

Release Date Price: kr39.11 (+5.93%)

Transcript

Key Points

Positve

Hansa Biopharma AB (STU:24H) reported a strong revenue growth of 135% in Q4 2025 compared to the same quarter last year.
The company successfully closed an equity round of SEK671.5 million, securing funding for operations into 2027.
Hansa Biopharma AB submitted a BLA application to the FDA in December 2025, with expectations of a PUFA date announcement soon.
The company announced plans to develop Hansa 5,487 for Guillain-Barre Syndrome, with trials expected to start before the end of the year.
Reorganization of the European commercial organization aims to improve transparency and accountability, potentially enhancing future performance.

Negative

The company expects a relatively weak revenue development in Q1 2026 due to ongoing change management implementations.
Challenges in the German market persist, with a pause in participation in the Eurotransplant priority program affecting operations.
The phase 3 study in anti-GBM disease did not meet its primary and key secondary endpoints, leading to no further planned trials in this area.
SG&A expenses increased by 15% in Q4 2025 compared to the same period in 2024, indicating rising operational costs.
The company faces uncertainties in the US market regarding reimbursement pathways and pricing strategies for the upcoming product launch.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

HNSA.ST - Hansa Biopharma AB
Q4 2025 Hansa Biopharma AB Earnings Call
Feb 11, 2026 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and welcome to the Hansa BioPharma 4th quarter in full year 2025 financial results conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the key followed by 0. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press, then 1 on a touchtone phone. To withdraw your question, please press 2.

We ask that you limit yourself to one question, please. Please note that this event is being recorded. I would now like to turn the conference over to Hansa BioPharma CEO Renee Aguiar Lukinder.

Please go ahead.

------------------------------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.